Beijing Cuiwei Tower (603123.SH) is expected to incur a net loss of 650 million to 690 million yuan in 2024.
Tsuiwei Co., Ltd. (603123.SH) releases a 2024 annual performance pre-loss announcement, estimating a net loss for the 2024 annual performance ...
Beijing Cuiwei Tower (603123.SH) has announced a forecasted net loss of 650-690 million yuan for the year 2024.
The main reasons for the expected loss in performance are:
1. The company's controlling subsidiary, Beijing Haike Rongtong Payment Service Co., Ltd., has been affected by a decline in industry transaction volume, increased difficulties in expanding business, and high fixed costs in the acquiring business, resulting in a significant decrease in operating performance.
2. The company's retail business revenue has declined due to the impact of the retail industry environment. The wholly-owned subsidiary, Contemporary Mall's Beijing Centergate Technologies store, has been closed for rebuilding since January 7, 2024, leading to operating losses in the retail business. Additionally, due to the impact of the retail business environment, the company has made adjustments to recognize deferred tax assets in the reporting period, which will have a certain impact on net profit.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025